PERCHERON THERAPEUTICS LIMITED — Director's Dealing 2012

Apr 25, 2012

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Antisense Therapeutics Limited(ASX:ANP)
**Name of Entity: **
	41 095 060 745
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr Mark Diamond
Date of LastNotice:	30 September 2011

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

director” should be disclosed in this part.
Direct or Indirect Interest		Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.		-
Date of change		26thApril 2012
No. of securities held prior to change			Shares		Options
		Direct	2,462,041		5,812,460
		Indirect
		Total	2,462,041		5,812,460
Class		Ordinary Shares
Number acquired			Shares		Options
		Direct	350,000		-
		Indirect			-
		Total	350,000		-
Number disposed					Options
				Shares	Options
		Direct
		Indirect
		**Total **

• See chapter 19 for defined terms.

Appendix 3Y Page 1

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation		$5,600
No. of securities held after change			Shares	Options
		Direct	2,812,041	5,812,460
		Indirect	-
		Total	2,812,041	5,812,460
Nature of changeExample: on-market trade, off-market trade, exercise of options,issueofsecuritiesunderdividendreinvestmentplan,participation in buy-back		On market acquisition

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Note: In the case of a company, interests whichdirector” should be disclosed in this part.	come within paragraph (ii) of the definition of “notifiable interest of a
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securitiesor contracts detailed above tradedduring a +closed period whereprior written clearance wasrequired?	No
If so, was prior written clearanceprovided to allow the trade toproceed during this period?	N/A
If prior written clearance wasprovided, on what date was thisprovided?	N/A

==> picture [37 x 22] intentionally omitted <==

The CFO Solution

26/04/2012

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011